The combination of vemurafenib and cobimetinib in advanced melanoma

View/ Open
Date
2016-11-01ICR Author
Author
Spain, L
Goode, E
McGovern, Y
Joshi, K
Larkin, J
Type
Journal Article
Metadata
Show full item recordCollections
Subject
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Vemurafenib
cobimetinib
advanced melanoma
BRAF mutation
MAPK pathway
BRAF-MUTATED MELANOMA
RANDOMIZED CONTROLLED-TRIAL
FREE SURVIVAL PFS
METASTATIC MELANOMA
MEK INHIBITION
OPEN-LABEL
POSITIVE MELANOMA
MUTANT MELANOMA
RAF INHIBITION
RESISTANCE
Research team
Melanoma and Kidney Cancer
Language
eng
License start date
2016-11-01
Citation
EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (11), pp. 1105 - 1111 (7)
Publisher
TAYLOR & FRANCIS LTD
Related items
Showing items related by title, author, creator and subject.
-
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol, KF; van den Bosch, T; Schreibelt, G; Mensink, HW; Keunen, JEE; et al. (2016-10) -
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.
Pulido, J; Kottke, T; Thompson, J; Galivo, F; Wongthida, P; et al. (2012-03-18)Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with established melanoma tumors. ... -
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett, E; Kottke, T; Thompson, J; Rajani, K; Zaidi, S; et al. (2017-01)The anti-tumour effects associated with oncolytic virus therapy are mediated significantly through immune-mediated mechanisms, which depend both on the type of virus and the route of delivery. Here, we show that intra-tumoral ...